An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
The COVID-19 pandemic is one of the greatest threats to human health in the 21st century
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …
Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic
KKW To, S Sridhar, KHY Chiu, DLL Hung… - Emerging microbes & …, 2021 - Taylor & Francis
Without modern medical management and vaccines, the severity of the Coronavirus
Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome (SARS) …
Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome (SARS) …
[HTML][HTML] Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
S Ramakrishnan, DV Nicolau, B Langford… - The Lancet …, 2021 - thelancet.com
Background Multiple early reports of patients admitted to hospital with COVID-19 showed
that patients with chronic respiratory disease were significantly under-represented in these …
that patients with chronic respiratory disease were significantly under-represented in these …
Association between mood disorders and risk of COVID-19 infection, hospitalization, and death: a systematic review and meta-analysis
Importance Preexisting noncommunicable diseases (eg, diabetes) increase the risk of
COVID-19 infection, hospitalization, and death. Mood disorders are associated with …
COVID-19 infection, hospitalization, and death. Mood disorders are associated with …
Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study
N Hoertel, M Sánchez-Rico, R Vernet, N Beeker… - Molecular …, 2021 - nature.com
A prior meta-analysis showed that antidepressant use in major depressive disorder was
associated with reduced plasma levels of several pro-inflammatory mediators, which have …
associated with reduced plasma levels of several pro-inflammatory mediators, which have …
Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2
TA Tummino, VV Rezelj, B Fischer, A Fischer… - Science, 2021 - science.org
Repurposing drugs as treatments for COVID-19, the disease caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has drawn much attention. Beginning …
respiratory syndrome coronavirus 2 (SARS-CoV-2), has drawn much attention. Beginning …
[HTML][HTML] Fluvoxamine: a review of its mechanism of action and its role in COVID-19
Fluvoxamine is a well-tolerated, widely available, inexpensive selective serotonin reuptake
inhibitor that has been shown in a small, double-blind, placebo-controlled, randomized …
inhibitor that has been shown in a small, double-blind, placebo-controlled, randomized …
Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants
Importance Antidepressant use may be associated with reduced levels of several
proinflammatory cytokines suggested to be involved with the development of severe COVID …
proinflammatory cytokines suggested to be involved with the development of severe COVID …
SARS-CoV-2 antiviral therapy
The development of effective antiviral therapy for COVID-19 is critical for those awaiting
vaccination, as well as for those who do not respond robustly to vaccination. This review …
vaccination, as well as for those who do not respond robustly to vaccination. This review …
Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19
D Seftel, DR Boulware - Open Forum Infectious Diseases, 2021 - academic.oup.com
We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-
19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to …
19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to …